iTeos Therapeutics Inc. (ITOS): Price and Financial Metrics


iTeos Therapeutics Inc. (ITOS): $20.87

0.27 (+1.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ITOS POWR Grades


  • ITOS scores best on the Value dimension, with a Value rank ahead of 98.79% of US stocks.
  • ITOS's strongest trending metric is Growth; it's been moving up over the last 179 days.
  • ITOS's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

ITOS Stock Summary

  • iTeos Therapeutics Inc's stock had its IPO on July 24, 2020, making it an older stock than merely 3.92% of US equities in our set.
  • In terms of twelve month growth in earnings before interest and taxes, iTeos Therapeutics Inc is reporting a growth rate of -773.31%; that's higher than merely 2.79% of US stocks.
  • Revenue growth over the past 12 months for iTeos Therapeutics Inc comes in at 230.65%, a number that bests 96.46% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to iTeos Therapeutics Inc, a group of peers worth examining would be PXLW, YMAB, TARS, MNOV, and UTHR.
  • ITOS's SEC filings can be seen here. And to visit iTeos Therapeutics Inc's official web site, go to www.iteostherapeutics.com.

ITOS Valuation Summary

  • 500 - Internal server error
  • ITOS's price/sales ratio has moved down 0.5 over the prior 13 months.
  • Over the past 13 months, ITOS's price/earnings ratio has gone up 7.8.

Below are key valuation metrics over time for ITOS.

Stock Date P/S P/B P/E EV/EBIT
ITOS 2021-08-31 NA 3.4 -15.0 -10.6
ITOS 2021-08-30 NA 3.4 -14.8 -10.5
ITOS 2021-08-27 NA 3.4 -14.8 -10.5
ITOS 2021-08-26 NA 3.3 -14.6 -10.2
ITOS 2021-08-25 NA 3.3 -14.4 -10.0
ITOS 2021-08-24 NA 3.3 -14.4 -10.1

ITOS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ITOS has a Quality Grade of D, ranking ahead of 24.17% of graded US stocks.
  • ITOS's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ITOS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA 44.562
2021-03-31 0 NA 60.016
2020-12-31 0 NA 15.977

ITOS Price Target

For more insight on analysts targets of ITOS, see our ITOS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $49.20 Average Broker Recommendation 1.3 (Strong Buy)

ITOS Stock Price Chart Interactive Chart >

Price chart for ITOS

ITOS Price/Volume Stats

Current price $20.87 52-week high $52.43
Prev. close $20.60 52-week low $16.21
Day low $19.86 Volume 343,500
Day high $21.36 Avg. volume 516,203
50-day MA $21.20 Dividend yield N/A
200-day MA $30.88 Market Cap 741.74M

iTeos Therapeutics Inc. (ITOS) Company Bio


iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Cambridge, MA.


ITOS Latest News Stream


Event/Time News Detail
Loading, please wait...

ITOS Latest Social Stream


Loading social stream, please wait...

View Full ITOS Social Stream

Latest ITOS News From Around the Web

Below are the latest news stories about iTeos Therapeutics Inc that investors may wish to consider to help them evaluate ITOS as an investment opportunity.

5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.

Yahoo | February 24, 2022

iTeos to Participate in Upcoming Investor Conferences in February

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 10, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in two upcoming virtual investor conferences in February: 11th Annual SVB Leerink Global Healthcare ConferenceDate

Yahoo | February 10, 2022

Jackson Creek Investment Advisors LLC Buys ITeos Therapeutics Inc, Extreme Networks Inc, SMART ...

Investment company Jackson Creek Investment Advisors LLC (Current Portfolio) buys ITeos Therapeutics Inc, Extreme Networks Inc, SMART Global Holdings Inc, BlueLinx Holdings Inc, Newmark Group Inc, sells OptimizeRx Corp, Ranger Oil Corp, Ranger Oil Corp, Ranger Oil Corp, Digital Turbine Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Jackson Creek Investment Advisors LLC.

Yahoo | February 1, 2022

Asymmetry Capital Management, L.P. Buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, ...

Investment company Asymmetry Capital Management, L.P. (Current Portfolio) buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, AbbVie Inc, IQVIA Holdings Inc, Centene Corp, sells Alkermes PLC, Medtronic PLC, Insulet Corp, Hologic Inc, Sage Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Asymmetry Capital Management, L.P..

Yahoo | January 19, 2022

iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 10, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today provided a clinical development plan for its anti-TIGIT monoclonal antibody, EOS-448, and its A2A receptor antagonist, inupadenant. iTeos also announced the promotion of Yvonne McGrath, Ph.D., to chief scie

Yahoo | January 10, 2022

Read More 'ITOS' Stories Here

ITOS Price Returns

1-mo 16.40%
3-mo -33.91%
6-mo -56.02%
1-year -17.41%
3-year N/A
5-year N/A
YTD -55.18%
2021 37.67%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4874 seconds.